Payment overview · 2025
General Payments
$565.55
29 reported records · 12 companies
Healthcare provider profile · identity verified
Michael A Laufer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE CORAL, FL · NPI 1164493946
Verified facts
What the public records show
CMS Open Payments records show Michael A Laufer, MD received $565.55 in general payments during 2025 across 29 reported records.
GlaxoSmithKline, LLC. accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.00 | 18.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.12 | 18.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.23 | 18.1% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $83.71 | 14.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $48.68 | 8.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.66 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.43 | 3.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.01 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.90 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.56 | 2.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.64 | 2.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.61 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $565.55 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $105.00 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $83.71 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.56 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $54.49 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $48.68 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $48.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.67 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.67 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1160 | 374 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1130 | 337 |
| Lisinopril | Lisinopril | 965 | 277 |
| Levothyroxine Sodium | Levothyroxine Sodium | 907 | 253 |
| Amlodipine Besylate | Amlodipine Besylate | 730 | 217 |
| Losartan Potassium | Losartan Potassium | 543 | 160 |
| Simvastatin | Simvastatin | 519 | 149 |
| Alprazolam | Alprazolam | 499 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 438 | 132 |
| Metformin Hcl | Metformin Hcl | 399 | 122 |
| Gabapentin | Gabapentin | 363 | 122 |
| Omeprazole | Omeprazole | 355 | 112 |
| Trazodone Hcl | Trazodone Hcl | 289 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 87 |
| Famotidine | Famotidine | 270 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 110 |
| Allopurinol | Allopurinol | 251 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 71 |
| Meloxicam | Meloxicam | 207 | 79 |
| Tramadol Hcl | Tramadol Hcl | 206 | 53 |
| Montelukast Sodium | Montelukast Sodium | 203 | 65 |
| Atenolol | Atenolol | 193 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 190 | 56 |
| Furosemide | Furosemide | 187 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 78 |
| Potassium Chloride | Potassium Chloride | 179 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 57 |
| Eliquis | Apixaban | 176 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 49 |
| Finasteride | Finasteride | 166 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 48 |
| Ibandronate Sodium | Ibandronate Sodium | 145 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 42 |
| Carvedilol | Carvedilol | 140 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 39 |
| Farxiga | Dapagliflozin Propanediol | 126 | 45 |
| Xarelto | Rivaroxaban | 118 | 32 |
| Ezetimibe | Ezetimibe | 117 | 40 |
| Synthroid | Levothyroxine Sodium | 116 | 33 |
| Glimepiride | Glimepiride | 115 | 32 |
| Temazepam | Temazepam | 114 | 28 |
| Celecoxib | Celecoxib | 108 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 32 |
| Sertraline Hcl | Sertraline Hcl | 103 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 103 | 88 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 32 |
| Lorazepam | Lorazepam | 100 | 22 |
| Metformin Hcl Er | Metformin Hcl | 93 | 29 |
| Ozempic | Semaglutide | 93 | 21 |
| Torsemide | Torsemide | 93 | 34 |
| Clonazepam | Clonazepam | 92 | 23 |
| Diazepam | Diazepam | 88 | 24 |
| Spironolactone | Spironolactone | 88 | 36 |
| Bupropion Xl | Bupropion Hcl | 87 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 27 |
| Benazepril Hcl | Benazepril Hcl | 81 | 20 |
| Mounjaro | Tirzepatide | 76 | 17 |
| Valsartan | Valsartan | 74 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 20 |
| Fenofibrate | Fenofibrate | 70 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 20 |
| Methylprednisolone | Methylprednisolone | 68 | 59 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 19 |
| Mirtazapine | Mirtazapine | 65 | 26 |
| Trulicity | Dulaglutide | 65 | 14 |
| Januvia | Sitagliptin Phosphate | 64 | 19 |
| Ramipril | Ramipril | 64 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 25 |
| Buspirone Hcl | Buspirone Hcl | 60 | 20 |
| Pregabalin | Pregabalin | 60 | 18 |
| Azelastine Hcl | Azelastine Hcl | 59 | 27 |
| Jardiance | Empagliflozin | 58 | 17 |
| Azithromycin | Azithromycin | 57 | 57 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 57 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 44 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 15 |
| Baclofen | Baclofen | 52 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 48 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 13 |
| Aripiprazole | Aripiprazole | 42 | 13 |
| Enalapril Maleate | Enalapril Maleate | 42 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 17 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Ibuprofen | Ibuprofen | 37 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 35 |
| Prednisone | Prednisone | 36 | 18 |
| Prolia | Denosumab | 36 | 19 |
| Estradiol | Estradiol | 35 | 11 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 14 |
| Primidone | Primidone | 34 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 34 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 16 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 32 | 11 |
| Glipizide | Glipizide | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 16 |
| Acyclovir | Acyclovir | 26 | 11 |
| Amoxicillin | Amoxicillin | 26 | 24 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Nystatin | Nystatin | 26 | 13 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 15 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $565.55 · 29 records | GlaxoSmithKline, LLC. | CAPVAXIVE, GARDASIL 9, GEMTESA, JARDIANCE, KISUNLA, Korlym, LEQVIO, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VENASEAL, VYEPTI, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error